HFO-1234ze(E) + HFA-134a
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucociliary Clearance
Conditions
Mucociliary Clearance
Trial Timeline
Jun 14, 2023 → Jul 22, 2024
NCT ID
NCT05755932About HFO-1234ze(E) + HFA-134a
HFO-1234ze(E) + HFA-134a is a phase 3 stage product being developed by AstraZeneca for Mucociliary Clearance. The current trial status is completed. This product is registered under clinical trial identifier NCT05755932. Target conditions include Mucociliary Clearance.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05755932 | Phase 3 | Completed |
Competing Products
1 competing product in Mucociliary Clearance
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose) | Sumitomo Pharma | Approved | 85 |